Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | UBE2C |
| Upstream (Parents) |
|---|
| (<<) CCNB1 → UBE2C |
| (<<) CCNB2 → UBE2C |
| (<<) CENPF → UBE2C |
| (<<) E2F1 → UBE2C |
| (<<) ELK3 → UBE2C |
| (<<) ITGB5 → UBE2C |
| (<<) PLK1 → UBE2C |
| (<<) RECK → UBE2C |
| (<<) SPAG5 → UBE2C |
| (<<) THOC4 → UBE2C |
| (<<) TK2 → UBE2C |
| (<<) TUBA1C → UBE2C |
| Downstream (Children) |
|---|
| UBE2C → ACAT2 (>>) |
| UBE2C → ADAM12 (>>) |
| UBE2C → ADORA2B (>>) |
| UBE2C → ANKRD27 (>>) |
| UBE2C → AQP3 (>>) |
| UBE2C → ASNS (>>) |
| UBE2C → BBS1 (>>) |
| UBE2C → CBFA2T3 (>>) |
| UBE2C → CBS (>>) |
| UBE2C → CCNA1 (>>) |
| UBE2C → CCNE1 (>>) |
| UBE2C → CD3EAP (>>) |
| UBE2C → CEBPB (>>) |
| UBE2C → CYP2U1 (>>) |
| UBE2C → E2F5 (>>) |
| UBE2C → E2F7 (>>) |
| UBE2C → EIF2C2 (>>) |
| UBE2C → EIF4EBP1 (>>) |
| UBE2C → FAM110C (>>) |
| UBE2C → FZD6 (>>) |
| UBE2C → GAL (>>) |
| UBE2C → GNAL (>>) |
| UBE2C → HDAC2 (>>) |
| UBE2C → HSPA14 (>>) |
| UBE2C → IL1R1 (>>) |
| UBE2C → MEGF6 (>>) |
| UBE2C → MMP3 (>>) |
| UBE2C → NMU (>>) |
| UBE2C → ODZ2 (>>) |
| UBE2C → PCDH7 (>>) |
| UBE2C → PFDN2 (>>) |
| UBE2C → PHGDH (>>) |
| UBE2C → PLA2R1 (>>) |
| UBE2C → PSAT1 (>>) |
| UBE2C → RORA (>>) |
| UBE2C → RPS6KB1 (>>) |
| UBE2C → RRAS2 (>>) |
| UBE2C → RRP9 (>>) |
| UBE2C → SCN4B (>>) |
| UBE2C → SEH1L (>>) |
| UBE2C → SHC2 (>>) |
| UBE2C → SLC7A5 (>>) |
| UBE2C → SMURF2 (>>) |
| UBE2C → SUMF1 (>>) |
| UBE2C → TAF1A (>>) |
| UBE2C → TARS (>>) |
| UBE2C → UBQLN1 (>>) |
| UBE2C → YRDC (>>) |
